Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00758251|
Recruitment Status : Completed
First Posted : September 25, 2008
Last Update Posted : December 10, 2010
The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment|
|Study Start Date :||September 2008|
|Primary Completion Date :||March 2009|
|Study Completion Date :||March 2009|
Adult schizophrenia patients already on Seroquel XR therapy
- Improvement in CGI scores and BPRS comparing visits 1 and 3. [ Time Frame: twice with 4 week interval ]
- To evaluate compliance to therapy [ Time Frame: twice with 4 week interval ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00758251
|Study Director:||Agrita Hartmane||AstraZeneca Latvia|